Valuing innovative endoscopic techniques: Hemostatic powder for the treatment of gastrointestinal tumor bleeding.
Journal
Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
25
07
2023
revised:
18
11
2023
accepted:
25
12
2023
medline:
7
1
2024
pubmed:
7
1
2024
entrez:
6
1
2024
Statut:
aheadofprint
Résumé
Access to new endoscopic treatment modalities often depends on price. To resolve this gap and therefore help to ensure that care delivery can occur on a clinical basis, we aimed to establish the value to insurers of novel hemostatic powder to treat gastrointestinal tumor bleeding. A decision-analytic model developed to assess the impact of endoscopic intervention on the risk of 30-day readmission for gastrointestinal bleeding from an insurer perspective, was adapted to assess gastrointestinal tumor bleeding with hemostatic powder or standard endoscopic therapy. Costs were derived from Medicare populations. Outcomes were derived from a recent multicenter randomized clinical trial. $651 to $1,613 to treat upper gastrointestinal tumor bleeding and $531 to $1,014 to treat lower gastrointestinal tumor bleeding based on risk reduction in 30-day hospital re-admission for re-bleeding. These valuations should represent medical device and incremental facility costs in addition to incremental physician and staff time. Coverage for novel endoscopic hemostatic powder therapy appears cost-saving to insurers.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Access to new endoscopic treatment modalities often depends on price. To resolve this gap and therefore help to ensure that care delivery can occur on a clinical basis, we aimed to establish the value to insurers of novel hemostatic powder to treat gastrointestinal tumor bleeding.
METHODS
METHODS
A decision-analytic model developed to assess the impact of endoscopic intervention on the risk of 30-day readmission for gastrointestinal bleeding from an insurer perspective, was adapted to assess gastrointestinal tumor bleeding with hemostatic powder or standard endoscopic therapy. Costs were derived from Medicare populations. Outcomes were derived from a recent multicenter randomized clinical trial.
RESULTS
RESULTS
$651 to $1,613 to treat upper gastrointestinal tumor bleeding and $531 to $1,014 to treat lower gastrointestinal tumor bleeding based on risk reduction in 30-day hospital re-admission for re-bleeding. These valuations should represent medical device and incremental facility costs in addition to incremental physician and staff time.
CONCLUSIONS
CONCLUSIONS
Coverage for novel endoscopic hemostatic powder therapy appears cost-saving to insurers.
Identifiants
pubmed: 38184119
pii: S0016-5107(24)00007-5
doi: 10.1016/j.gie.2023.12.036
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.